DBV Technologies

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood.

Filings

114 filings

All Inside information114 Threshold crossing51 Earnings release10 Universal registration document2 Half-year financial report2

30/07/2026
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
Inside informationFR
17/07/2026
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
Inside informationFR
16/07/2026
DBV Technologies Announces the Filing of its 2026 Half-Year Report ? Conditions for Accessing or Consulting the Report
Inside informationFR
06/07/2026
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Inside informationFR
29/06/2026
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
Inside informationFR
23/06/2026
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
Inside informationFR
09/06/2026
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
Inside informationFR
08/06/2026
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
Inside informationFR
05/06/2026
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Inside informationFR
03/06/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026
Inside information
03/06/2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mai 2026
Inside informationFrench
03/06/2026
DBV Technologies Announces the Results of its 2026 Combined General Meeting
Inside information
03/06/2026
DBV Technologies annonce les résultats de son Assemblée Générale Mixte du 3 juin 2026
Inside informationFrench
03/06/2026
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
Inside informationFR
13/05/2026
Combined General Meeting of June 3, 2026
Inside informationFR
12/05/2026
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
Inside informationFR
02/04/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
Inside informationFR
26/03/2026
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
Inside informationFR
24/03/2026
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
Inside informationFR
04/03/2026
DBV Technologies to Participate in Upcoming March Investor Conferences
Inside informationFR
03/03/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026
Inside informationFR
28/02/2026
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
Inside informationFR
10/02/2026
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
Inside informationFR
09/02/2026
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
Inside informationFR
05/02/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
Inside informationFR
17/01/2026
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
Inside informationFR
12/01/2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2025
Inside informationFrench
07/01/2026
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Inside informationFR
05/01/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Inside information
16/12/2025
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Inside informationFR
02/12/2025
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025
Inside informationFrench
12/11/2025
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Inside informationFR
04/11/2025
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Inside informationFR
03/11/2025
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Inside information
03/11/2025
DBV Technologies annonce la nomination de Kevin Trapp, dirigeant chevronné du secteur, au poste de Directeur Commercial
Inside informationFrench
03/11/2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
Inside information
03/11/2025
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2025
Inside informationFrench
30/10/2025
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Inside informationFR
30/10/2025
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
Inside informationFR
29/10/2025
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Inside informationFR
28/10/2025
DBV Technologies Reports Third Quarter 2025 Financial Results
Inside informationFR
06/10/2025
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Inside informationFR
18/09/2025
DBV Technologies Announces Resignation of Board Member
Inside informationFR
05/09/2025
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
Inside informationFR
03/09/2025
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Inside informationFR
01/08/2025
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
Inside information

About

ISIN: FR0010417345
Ticker: DBV
LEI: 969500PVBQFWQKVDMD80
Sector: Health care
Founded: 2002
Country of registration: FR
Last filing: 30/07/2026, 23:40

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive